VIR: Vir Bio Price-to-Revenue Coefficient

Symbol and logo of brand Vir Biotechnology Inc (VIR)

The P/S trajectory illustrates the market valuation of Vir Biotechnology, Inc. (VIR), with the current level standing at 6.80. Vir Biotechnology, Inc. (VIR) develops antiviral drugs against influenza and hepatitis B through strategic alliances with scientific foundations. Production and testing are outsourced to third-party contractors. High liquidity enables the development of new platforms while protecting shareholder capital from dilution.

VIR: vir.bio Market Cap to Revenue 07/04/2022 - 11/13/2026

Analytical breakdowns for Vir Bio (VIR)

- current price and projected stock value:
Price Chart vir.bio|VIR - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Vir Bio|VIR - Total Company Value
- company book value details:
Accounting Value of a Share Vir Biotechnology|VIR - Company Net Assets|Market Value to Book Value vir.bio|VIR - Company Total Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Vir Biotechnology, Inc.|VIR - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Vir Corp|VIR - Company Debts|Debts to Book Value Vir Bio|VIR - Company Long-Term Liabilities|Amount of Current Liabilities Vir Biotechnology|Immediate Liquidity vir.bio
- earnings and valuation multiples information:
VIR - Net Profit|Future Profit Vir Biotechnology, Inc.|VIR - P/E Multiple|Future Price to Earnings Multiple Vir Biotechnology Inc|VIR - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Vir Bio|VIR - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Vir Biotechnology|VIR - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months vir.bio|VIR - Earnings per share growth in current year|Expected net earnings per share growth next year Vir Biotechnology, Inc.
- sales revenue and business income indicators:
VIR - Revenue and Sales Volume|Company Sales Forecast vir.bio|VIR - Market Cap to Revenue|Market Cap to Future Revenue Ratio Vir Bio
Fundamental company analysis:VIR - vir.bio
Product sample of Vir Biotechnology, Inc.

For Vir Biotechnology, Inc. (VIR), which is adapting its portfolio following a decline in demand for antivirals, the P/S ratio serves as an indicator of the market value of every dollar of revenue generated. Analyzing the price-to-sales ratio allows for an assessment of capitalization relative to actual sales, filtering out temporary noise and confirming business resilience driven by a strong scientific core and significant liquidity reserves.

Who Vir Biotechnology, Inc. competes with

Price-to-Revenue Ratio GILD (gilead.com)|P/S Multiple CDTX (Cidara Therapeutics Inc)|Price-to-Revenue Coefficient Novavax Inc (NVAX)|CVAC - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio VALN (Valneva Vaccines)|SIGA (SIGA Technologies, Inc.) - Market Cap to Revenue|emergentbiosolutions.com - Market Capitalization-to-Revenue Ratio|AVIR (Atea Pharmaceuticals, Inc.) - P/S Multiple|Price-to-Revenue Ratio IVVD|P/S Multiple ENTA|Price-to-Revenue Coefficient Inovio Pharma|Price-to-Revenue Ratio HilleVax, Inc. HLVX|kalaristx.com (KLRS) - Price to Sales|DYAI: Market Cap to Revenue|NanoViricides, Inc. - Market Cap to Sales Volume|TLPH: P/S Multiple|Price to Sales Cocrystal Pharma Corp (COCP)|TRAW (Traws Pharma Inc) - P/S Multiple|Market Cap to Revenue Virios Therapeutics (DWTX)|P/S Multiple QLGN|ALVR (allovir.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio VBI Vaccines VBIV|VIRI: Market Cap to Revenue Ratio|VXRT - Price-to-Revenue Ratio